QSQuantSignals Research/Studies
Try FST free

← All studies

FAIL

The daily MACD trend and RSI turning signal on large US stocks and ETFs: does it call the next move?

When the daily MACD trend and an RSI turning point agree, does the stock or ETF keep moving that way by the next close or ten sessions later, by enough to beat trading costs?

None of the four pre-registered trials passed, so the answer is no edge at the bar the study fixed. The judged discovery sample is 23 names, not 34: ten names (EWZ, GDX, GLD, LQD, SLV, TLT, TQQQ, XLE, XLF and META) have daily data only from 2021-10-25 and IBIT only from 2022-09-08, after the 2021-04-19 discovery cut, and SNDK has no bars in the counted window. None of those eleven late counted names contributes a discovery signal, and SNDK contributes none at all; the 34-name count is the 23 discovery names plus the eleven late names. On those 23 names from 2016 to April 2021, calls had 1,879 signals and made +0.211% net to the next close (month-clustered lower bound +0.058%, stress +0.148%, MACD-only baseline +0.063%) and +1.372% at ten sessions (lower bound +0.644%, stress +1.310%, baseline +1.050%). Both call trials fail only the deflated Sharpe test, at 0.0001 and 0.0073 against 0.80; the deflated Sharpe is judged at the family's 14 effective trials, not at the 2,009 trials run across all studies when it was judged. Puts had 1,817 signals and lost 0.187% to the next close (lower bound -0.422%, stress -0.253%, 1 of 5 years positive) and 1.643% at ten sessions (lower bound -2.508%, stress -1.719%, 0 of 5 years, and worse than the MACD-only baseline by 0.055%); both put trials fail the mean, bound, stress, year and deflated Sharpe checks. Nothing passed discovery, so validation and the holdout were never read; the holdout stays sealed. The study prices the stock or ETF, not the option a ten-day trade would buy, on a fixed survivor list in one rising regime, with closes split-adjusted but not dividend-adjusted.

Backtested by QS Research

Pre-registration

The pre-registration fixed the rule before the data was read: on closed daily bars, MACD(12,26,9) sets the trend and RSI(14) turning at its own 14-day average sets the entry; only the first bar of a run counts. The universe is 35 large US stocks and ETFs, a survivor list, with no new signal until 34 daily bars exist. Four trials were fixed: calls and puts, each held to the next close and to the close ten sessions later, pooled across the names from 2016-01-04 to 2024-10-29. Each trial is judged on at least 30 signals, a positive mean net of two times the liquidity tier's per-side cost (plus borrow on puts), a positive month-clustered one-sided lower bound at 0.05/4, a deflated Sharpe of at least 0.80, at most two losing years with at least half the years positive, a positive mean at double costs, and a positive edge over the same-side MACD-only baseline. The 60/20/20 split is by signal date; the holdout opens only for a trial that passes validation. Seventy earlier looks at the same daily rule are counted in the family, so the deflated Sharpe is judged at N = 14. Amendment 1, approved before the run, replaced the minute-data source with a pinned daily-bar snapshot for all 35 names, split-adjusted and not dividend-adjusted, because the minute store held only 19 of the 35. The discovery sample is 23 names; the other eleven counted names start after the discovery cut (ten on 2021-10-25, IBIT on 2022-09-08), and SNDK has no bars in the counted window.

Registered 2026-11-14

Amendments

A holdout sample is sealed: its results stay unread until the study is final.

Trials · 4 trials · 0 passed · judged at N = 14 trials; 2965 trials run in total

TrialVerdict
Calls (up signals), held to the next closeFAILcounted
Calls (up signals), held 10 sessionsFAILcounted
Puts (down signals), held to the next closeFAILcounted
Puts (down signals), held 10 sessionsFAILcounted

Limitations

The numbers: every trial's checks, metrics, curve and yearly results, and the provenance

2 published versions · current 83c7c95d344c2482, published 2026-11-21

Put these signals to work

This page is free. Members get the live version of every QS Research signal. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans